# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Vijay Kumar maintains Baxter Intl (NYSE:BAX) with a Outperform and lowers the price target from $...
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—includ...
- SEC Filing
The S&P 500 Index is up over 200% over the past decade, but 22 stocks have declined during that period, and one is set to b...
https://www.fda.gov/medical-devices/medical-device-recalls/early-alert-infusion-pump-issue-baxter-0
Barclays analyst Matt Miksic maintains Baxter Intl (NYSE:BAX) with a Overweight and lowers the price target from $41 to $36.
Stifel analyst Rick Wise downgrades Baxter Intl (NYSE:BAX) from Buy to Hold and lowers the price target from $36 to $25.